Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FTC Adds Public Citizen Alum To Senior Staff

This article was originally published in The Pink Sheet Daily

Executive Summary

David Vladeck, former head of Public Citizen Litigation Group, is named director of FTC’s Bureau of Consumer Protection as Chairman Leibowitz sets his leadership team.

You may also be interested in...



Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits

Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support

Supreme Court’s Wyeth v. Levine Ruling Returns Industry To Status Quo On Pre-Emption

The court finds that FDA-approved labeling does not pre-empt individuals from bringing product liability suits under state law.

Biosimilar Competition Debate: Must Products Be Interchangable To Generate Savings?

FTC hears arguments on whether the number of competitors, or their pharmacy-level substitutability, drives prices lower.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS069269

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel